FDA found Incredible Products’ GELBACT hand sanitizer labeled 80% ethanol contained 67% methanol and little ethanol.
What happened
FDA detained and refused admission of a batch of GELBACT ANTIBACTERIAL HAND GEL at the U.S. border and tested it. The batch was labeled to contain 80% ethanol, but FDA found an average of 1.2% ethanol and 67% methanol. FDA also cited the product as an unapproved new drug and misbranded; the company recalled it nationwide on August 6, 2020, and FDA placed the firm’s drugs on Import Alert 66-78.
What FDA found
The hand sanitizer’s labeled active ingredient, ethanol, was substituted in whole or in part with methanol, a dangerous chemical.
FD&C Act section 501(d)(2), 21 U.S.C. 351(d)(2)The methanol substitution showed that quality assurance at the facility was not working under CGMP requirements.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)The product is an unapproved new drug because FDA has no approved application for it and it does not meet the conditions for marketing without approval under section 505G.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d); section 505G, 21 U.S.C. 355hThe product is misbranded because it is dangerous to health when used as labeled as a hand sanitizer.
FD&C Act section 502(j), 21 U.S.C. 352(j)The label says the product contains 80% ethanol, but testing found less ethanol and undeclared methanol, making the labeling false or misleading and failing to list methanol as an ingredient.
FD&C Act sections 502(a) and 502(e)(1)(A), 21 U.S.C. 352(a) and 352(e)(1)(A)The label does not give a U.S. address or telephone number for reporting serious adverse events.
FD&C Act section 502(x), 21 U.S.C. 352(x)
What FDA wants
FDA asks the company to respond in writing within 15 working days with a detailed investigation into the methanol substitution, lists of raw materials and suppliers and shipped batches with reconciliation, complete batch records, and corrective action for relying on certificates of analysis for incoming alcohol. FDA also recommends a qualified CGMP consultant and a regulatory meeting if the firm wants to manufacture drugs for the U.S. in the future.
Who should pay attention
- U.S. importers and distributors of hand sanitizer
- retailers and wholesalers selling consumer hand sanitizer
- quality teams that rely on supplier certificates of analysis for alcohol raw materials
This is a summary. Read the original letter on fda.gov.